Data featured in oral presentation at ENDO 2026 show that dual MC3R/MC4R activation drives weight loss, limits rebound, and preserves lean mass in obese nonhuman primates ... .
Data featured in oral presentation at ENDO 2026 show that dual MC3R/MC4R activation drives weight loss, limits rebound, and preserves lean mass in obese nonhuman primates ...Dual MC3R/MC4R Activation ...
Dual Activation of MC3R and MC4RDrivesWeight Loss and Reduces Food Intake in Male Primates with Obesity ... Kalohexis is currently developing a novel oral dual MC3R/MC4R agonist, 710GO, which ...